Quick Answer
Context Therapeutics Inc. reported Net Income Loss of -$36.12 million for the year ending 2025.
- Context Therapeutics Inc. showed a decrease of -35.2% in Net Income Loss from 2024 to 2025.
- This data is from Context Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $826.5 thousand | Q2 2020: $7.48 million | Q3 2020: -$876.2 thousand | Q1 2021: -$892.0 thousand | Q2 2021: -$5.03 million | Q3 2021: -$1.44 million | Q1 2022: -$3.44 million | Q2 2022: -$3.99 million | Q3 2022: -$3.85 million | Q1 2023: -$6.31 million | Q2 2023: -$5.01 million | Q3 2023: -$5.87 million | Q1 2024: -$3.67 million | Q2 2024: -$2.25 million | Q3 2024: -$17.46 million | Q1 2025: -$4.58 million | Q2 2025: -$8.83 million | Q3 2025: -$9.69 million.
- Over the full 6 years of available data (2020 to 2025), Context Therapeutics Inc.'s Net Income Loss has declined by 643.7%.
- Historical annual values: Fiscal year 2025: -$36.12 million | Fiscal year 2024: -$26.73 million | Fiscal year 2023: -$23.96 million | Fiscal year 2022: -$14.84 million | Fiscal year 2021: -$10.46 million | Fiscal year 2020: $6.64 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: